Market By Gender, End-use And Geography | Forecast 2019-2027
The Triton Market Research report states that the Middle East & African infertility (testing and treatment) market is expected to grow in terms of revenue with a CAGR of 6.43% during the forecast period 2019-2027.
The countries scrutinized in the report of infertility (testing and treatment) market in the Middle East & Africa are:
• United Arab Emirates
• Turkey
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa.
Report scope can be customized per your requirements. Request For Customization
In-vitro fertilization is the most widely adopted means for infertility treatments in the region and is prominently used by couples with fertility problems, single mothers and others. Increasing government initiatives for the development of healthcare infrastructure, growing lifestyle & gynecological disorders in certain countries of MEA, decreasing rate of pregnancies amongst women and rising population are the factors responsible for the growth of IVF in the region. However, unawareness of advanced fertilization technologies, the high cost required for running the IVF procedure, lack of technical experts and scarcity of advanced in-vitro fertilization methods are expected to restrain the growth of the market. Ethical concerns in many regions of the Middle East have also restrained the market growth.
Technology enables parents to select the baby’s complexion, hair color, gender and so on. However, all of these technological advancements have to undergo tests and pass the regulatory requirements. Over five million babies have been born through IVF technology in the last two decades. With the passage of time, technology is improving, and infertility treatment is improved. Research and development have led to other methods for infertility treatment such as ICSI. The cost of this treatment is high but varies in different countries. In ICSI, the embryologist injects the sperm directly into the cytoplasm or center of the egg for fertilization. In ICSI technology, instead of exposing the egg to thousands of sperm for fertilization, the healthy sperm is injected directly into the egg. Thus, technological advancements will go a long way in boosting the market growth.
Male infertility is defined as the inability of the male to cause pregnancy in a fertile female. It has been seen that males are not open to talking about their experiences as freely as females. The feelings of fertility and sexual competence are closely related in their mind. Most men take virility and infertility to be the same. Often men feel that infertility is a reflection on their sexual competence and that will lead to social ridicule. Thus, a large section of infertile males are reluctant to seek treatment for their infertility issues. This is one of the factors restraining market growth.
1. INFERTILITY
(TESTING AND TREATMENT) MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. MARKET
DEFINITION
2.2. KEY
INSIGHTS
2.2.1. IVF
DOMINATES THE FEMALE TREATMENT MARKET
2.2.2. OXIDATIVE
STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET
2.3. PORTER’S
FIVE FORCE ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTE
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. INTENSITY
OF COMPETITIVE RIVALRY
2.4. KEY
IMPACT ANALYSIS
2.4.1. TREATMENT
OPTIONS
2.4.2. QUALITY
OF MEDICAL PROCEDURES
2.4.3. PRICE
OF TREATMENTS
2.4.4. SHIFT
TOWARDS MEDICAL TOURISM
2.4.5. REIMBURSEMENT
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. VENDOR
SCORECARD
2.7. INDUSTRY
COMPONENTS
2.7.1. RAW
MATERIAL PROCUREMENT
2.7.2. MANUFACTURING
2.7.3. SUPPLY
LOGISTICS
2.7.4. DISTRIBUTION
CHANNELS
2.7.5. END-USERS
2.8. REGULATORY
FRAMEWORK
2.9. MARKET
DRIVERS
2.9.1. RISE
IN INFERTILITY AND TREATMENT AWARENESS
2.9.2. MEDICAL
TOURISM IN FERTILITY TREATMENTS
2.9.3. SURROGACY
LAWS ARE GETTING MORE DEFINED
2.9.4. HEALTHCARE
ADVANCES HAVE FINE-TUNED FERTILITY TREATMENT
2.9.5. INCREASING
EFFECTIVENESS OF TREATMENTS
2.9.6. HEALTHIER
DONOR EGGS
2.9.7. INTRODUCTION
OF NEW TESTING DEVICES
2.10.
MARKET RESTRAINTS
2.10.1.
TREATMENT PROCEDURE OUT OF
REACH FOR MANY DUE TO HIGH COSTS
2.10.2.
COUNTRY-WISE REGULATORY ISSUES
2.11.
MARKET OPPORTUNITIES
2.11.1.
REDUCING THE COST OF TREATMENT
TO MAKE IT MORE ACCESSIBLE
2.11.2.
IVF ATTRACTING INVESTMENTS
FROM PRIVATE EQUITY INVESTORS
2.11.3.
DIY TESTING INCREASING ACCESS
AND REDUCING COST
2.12.
MARKET CHALLENGES
2.12.1.
INFERTILITY CONSIDERED A
SOCIAL TABOO AMONGST MEN
2.12.2.
PERILS OF MULTIPLE PREGNANCIES
2.12.3.
TRADITIONAL TREATMENTS USED
WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS
3. INFERTILITY
(TESTING AND TREATMENT) MARKET OUTLOOK - BY GENDER
3.1. MALE
GENDER
3.1.1. TESTING
3.1.1.1. DNA
FRAGMENTATION
3.1.1.2. OXIDATIVE
STRESS ANALYSIS
3.1.1.3. SPERM
PENETRATION ASSAY
3.1.1.4. COMPUTER-ASSISTED
SEMEN ANALYSIS (CASA)
3.1.1.5. SPERM
AGGLUTINATION
3.1.1.6. MICROSCOPIC
EXAMINATION
3.1.1.7. OTHERS
3.1.2. TREATMENT
3.2. FEMALE
GENDER
3.2.1. FEMALE
INFERTILITY TESTING
3.2.1.1. OVULATION
TESTING
3.2.1.2. HYSTEROSALPINGOGRAPHY
3.2.1.3. LAPAROSCOPY
3.2.1.4. TRANSVAGINAL
ULTRASOUND
3.2.1.5. OVARIAN
RESERVE TESTING
3.2.1.6. HORMONAL
LEVEL TESTING
3.2.1.7. OTHERS
3.2.2. TREATMENT
4. INFERTILITY
(TESTING AND TREATMENT) MARKET OUTLOOK - BY END-USE
4.1. FERTILITY
CLINICS
4.2. HOSPITALS
4.3. SURGICAL
CENTERS
4.4. CLINICAL
RESEARCH INSTITUTES
5. INFERTILITY (TESTING AND TREATMENT) MARKET - REGIONAL OUTLOOK
5.1. UNITED
ARAB EMIRATES
5.2. TURKEY
5.3. SAUDI
ARABIA
5.4. SOUTH
AFRICA
5.5. REST
OF MIDDLE EAST & AFRICA
6. COMPETITIVE
LANDSCAPE
6.1. ANDROLOGY
SOLUTIONS
6.2. ENDO
PHARMACEUTICALS
6.3. PROGYNY
6.4. FERRING
PHARMACEUTICALS
6.5. GENEA
6.6. HALOTECH
DNA
6.7. IRVINE
SCIENTIFIC
6.8. MERCK
6.9. ORIGIO
6.10.
OVASCIENCE
6.11.
VITROLIFE AB
6.12.
THERMO FISHER SCIENTIFIC, INC.
6.13.
THE COOPER COMPANIES, INC.
6.14.
QUEST DIAGNOSTIC
6.15.
ESCO MICRO PTE. LTD.
7. RESEARCH
METHODOLOGY & SCOPE
7.1. RESEARCH
SCOPE & DELIVERABLES
7.1.1. OBJECTIVES
OF STUDY
7.2. SOURCES
OF DATA
7.2.1. PRIMARY
DATA SOURCES
7.2.2. SECONDARY
DATA SOURCES
7.3. RESEARCH
METHODOLOGY
7.3.1. EVALUATION
OF PROPOSED MARKET
7.3.2. IDENTIFICATION
OF DATA SOURCES
7.3.3. ASSESSMENT
OF MARKET DETERMINANTS
7.3.4. DATA
COLLECTION
7.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY COUNTRY, 2019-2027 (IN $ MILLION)
TABLE 2: MARKET ATTRACTIVENESS INDEX
TABLE 3: VENDOR SCORECARD
TABLE 4: REGULATORY FRAMEWORK
TABLE 5: AVERAGE COST COMPARISON OF INFERTILITY
TREATMENTS
TABLE 6: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY GENDER, 2019-2027, (IN $ MILLION)
TABLE 7: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027, (IN $ MILLION)
TABLE 8: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY MALE INFERTILITY TESTING, 2019-2027, (IN $
MILLION)
TABLE 9: PROS AND CONS OF DNA SHARING METHODS
TABLE 10: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027, (IN $ MILLION)
TABLE 11: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027, (IN $
MILLION)
TABLE 12: COST OF OVULATION TESTING KITS IN THE US
TABLE 13: COST OF HORMONAL TEST IN THE US
TABLE 14: AVERAGE COST OF SOME INFERTILITY TREATMENTS
TABLE 15: SOME COMMON DRUG THERAPIES
TABLE 16: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)
TABLE 17: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY GENDER, 2019-2027 (IN $ MILLION)
TABLE 18: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027 (IN $ MILLION)
TABLE 19: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY MALE INFERTILITY TESTING, 2019-2027 (IN $
MILLION)
TABLE 20: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)
TABLE 21: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $
MILLION)
TABLE 22: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY END-USE, 2019-2027 (IN $ MILLION)
FIGURE 1: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY END-USER, 2018 & 2027 (IN %)
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: INDUSTRY COMPONENTS
FIGURE 5: MAJOR FERTILITY TREATMENT DESTINATION
RANKING
FIGURE 6: CLINICAL ALGORITHM FOR THE EVALUATION OF
INFERTILE WOMAN
FIGURE 7: RATE OF MULTIPLE DELIVERIES
FIGURE 8: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY MALE GENDER, 2019-2027 (IN $ MILLION)
FIGURE 9: MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, BY TESTING, 2019-2027 (IN $ MILLION)
FIGURE 10: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY DNA FRAGMENTATION, 2019-2027 (IN $ MILLION)
FIGURE 11: CAUSES OF SPERM DNA FRAGMENTATION
FIGURE 12: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY OXIDATIVE STRESS ANALYSIS, 2019-2027 (IN $ MILLION)
FIGURE 13: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY SPERM PENETRATION ASSAY, 2019-2027 (IN $ MILLION)
FIGURE 14: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY COMPUTER-ASSISTED SEMEN ANALYSIS, 2019-2027 (IN $
MILLION)
FIGURE 15: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY SPERM AGGLUTINATION, 2019-2027 (IN $ MILLION)
FIGURE 16: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY MICROSCOPIC EXAMINATION, 2019-2027 (IN $ MILLION)
FIGURE 17: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 18: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY TREATMENT, 2019-2027 (IN $ MILLION)
FIGURE 19: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY FEMALE GENDER, 2019-2027 (IN $ MILLION)
FIGURE 20: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY FEMALE INFERTILITY TESTING, 2019-2027 (IN $ MILLION)
FIGURE 21: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY OVULATION TESTING, 2019-2027 (IN $ MILLION)
FIGURE 22: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY HYSTEROSALPINGOGRAPHY, 2019-2027 (IN $ MILLION)
FIGURE 23: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY LAPAROSCOPY, 2019-2027 (IN $ MILLION)
FIGURE 24: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY TRANSVAGINAL ULTRASOUND, 2019-2027 (IN $ MILLION)
FIGURE 25: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY OVARIAN RESERVE TESTING, 2019-2027 (IN $ MILLION)
FIGURE 26: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY HORMONAL LEVEL TESTING, 2019-2027 (IN $ MILLION)
FIGURE 27: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY OTHERS, 2019-2027 (IN $ MILLION)
FIGURE 28: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY FEMALE INFERTILITY TREATMENT, 2019-2027 (IN $
MILLION)
FIGURE 29: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY FERTILITY CLINICS, 2019-2027 (IN $ MILLION)
FIGURE 30: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY HOSPITALS, 2019-2027 (IN $ MILLION)
FIGURE 31: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY SURGICAL CENTERS, 2019-2027 (IN $ MILLION)
FIGURE 32: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, BY CLINICAL RESEARCH INSTITUTES, 2019-2027 (IN $
MILLION)
FIGURE 33: MIDDLE EAST & AFRICA INFERTILITY (TESTING
AND TREATMENT) MARKET, REGIONAL OUTLOOK, 2018 & 2027 (IN %)
FIGURE 34: UNITED ARAB EMIRATES INFERTILITY (TESTING AND
TREATMENT) MARKET, 2019-2027 (IN $ MILLION)
FIGURE 35: TURKEY INFERTILITY (TESTING AND TREATMENT)
MARKET, 2019-2027 (IN $ MILLION)
FIGURE 36: SAUDI ARABIA INFERTILITY (TESTING AND
TREATMENT) MARKET, 2019-2027 (IN $ MILLION)
FIGURE 37: SOUTH AFRICA INFERTILITY (TESTING AND
TREATMENT) MARKET, 2019-2027 (IN $ MILLION)
FIGURE 38: REST OF MIDDLE EAST & AFRICA INFERTILITY
(TESTING AND TREATMENT) MARKET, 2019-2027 (IN $ MILLION)